MyFinsight
Home
Blog
About
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$68,335K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Share-based compensation
Accrued personnel-related expens...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Receivables from collaborative a...
Income tax payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-5,898
-4,933
61,024
3,615
Depreciation and amortization
367
381
399
405
Amortization and accretion on investment securities, net
937
602
1,310
771
Future royalty payment contingency interest accretion
-
-
582
573
Share-based compensation
5,990
4,504
4,480
4,576
Loss on disposal of property and equipment
-
-
0
0
Amortization of right-of-use assets
1,076
1,056
1,107
1,002
Deferred income taxes
-218
-2,999
30
-11,549
Other
-26
-42
-6
22
Receivables from collaborative and licensing arrangements
4,796
-29,954
27,272
-3,652
Receivables from milestones and royalty assets
0
0
-
0
Prepaid clinical and development services
-
-
0
0
Other prepaid and current assets
1,252
-1,666
814
1,179
Right-of-use lease assets
1
-314
28
-41
Future contingent milestone and royalty assets
-
-
0
0
Other assets
-331
-1,025
-251
413
Accounts payable
-448
-1,468
355
538
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities
4,684
-4,867
-1,275
3,606
Operating lease liabilities
-1,935
-2,199
-1,892
-1,862
Unrecognized tax benefits
1,333
1,474
6,515
1,360
Income tax payable
-3,508
-
-
-1,779
Other long-term liabilities
0
-69
-1
-1
Net cash provided by operating activities
-6,965
73,279
-6,064
-6,508
Purchases of property and equipment
-
-
8
0
Purchases of marketable securities
101,899
43,407
64,929
124,746
Maturities of marketable securities
41,496
96,000
65,525
24,500
Net cash used in investing activities
-60,403
52,593
588
-100,246
Proceeds from the sale of ordinary shares
-
-
0
0
Proceeds from option exercises
1,137
241
488
278
Repurchase of shares to satisfy tax withholding
2,104
5,818
1,979
678
Net cash used in financing activities
-967
-5,577
-1,491
-400
Net increase in cash, cash equivalents, and restricted cash
-68,335
120,295
-6,967
-107,154
Cash, cash equivalents, and restricted cash at beginning of period
288,937
168,642
175,609
38,633
Cash, cash equivalents, and restricted cash at end of period
220,602
288,937
168,642
175,609
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in
cash, cash...
-$68,335K
(-127.99%↓ Y/Y)
Maturities of marketable
securities
$41,496K
(-21.63%↓ Y/Y)
Share-based compensation
$5,990K
(-36.41%↓ Y/Y)
Accrued
personnel-related expenses,...
$4,684K
(179.14%↑ Y/Y)
Unrecognized tax benefits
$1,333K
(-48.85%↓ Y/Y)
Amortization of right-of-use
assets
$1,076K
(-43.55%↓ Y/Y)
Depreciation and
amortization
$367K
(-55.35%↓ Y/Y)
Other assets
-$331K
(-136.17%↓ Y/Y)
Other
-$26K
(-135.62%↓ Y/Y)
Proceeds from option
exercises
$1,137K
Net cash used in
investing activities
-$60,403K
(-973.64%↓ Y/Y)
Net cash provided by
operating activities
-$6,965K
(-102.77%↓ Y/Y)
Net cash used in
financing activities
-$967K
(28.74%↑ Y/Y)
Canceled cashflow
$41,496K
Canceled cashflow
$13,807K
Canceled cashflow
$1,137K
Purchases of marketable
securities
$101,899K
(74.06%↑ Y/Y)
Net income (loss)
-$5,898K
(-114.30%↓ Y/Y)
Receivables from
collaborative and licensing...
$4,796K
(37.86%↑ Y/Y)
Repurchase of shares to
satisfy tax withholding
$2,104K
(52.80%↑ Y/Y)
Income tax payable
-$3,508K
(-116.83%↓ Y/Y)
Operating lease
liabilities
-$1,935K
(42.46%↑ Y/Y)
something is missing
-$1,779K
Other prepaid and
current assets
$1,252K
(-8.41%↓ Y/Y)
Amortization and accretion on
investment securities, net
$937K
(25.10%↑ Y/Y)
Accounts payable
-$448K
(20.99%↑ Y/Y)
Deferred income taxes
-$218K
(98.26%↑ Y/Y)
Right-of-use lease assets
$1K
(-97.78%↓ Y/Y)
Buy us a coffee